{"id":"W2140587309","doi":"10.1016/s1470-2045(12)70490-4","title":"Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study","year":2012,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":550,"is_retracted":false,"has_abstract":false,"ca_institutions":"Toronto General Hospital; Vancouver General Hospital","funders":"","keywords":"Medicine; Placebo; Clinical endpoint; Internal medicine; Hepatocellular carcinoma; Sorafenib; Population; Neutropenia; Performance status; Randomized controlled trial; Surgery; Oncology; Cancer; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001471404,0.002237046,0.00454516,0.000454267,0.0004023105,0.001160006,0.0009083105,0.002121258,0.008329206],"category_scores_gemma":[0.001777526,0.0009815547,0.002251189,0.0004687229,0.001281074,0.001215203,0.0003877283,0.002951118,0.001483593],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009144717,"about_ca_system_score_gemma":0.0009631311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001208583,"about_ca_topic_score_gemma":0.002220711,"domain_scores_codex":[0.9994205,0.000301048,0.00003301319,0.00009684663,0.00003805227,0.0001106329],"domain_scores_gemma":[0.9992181,0.0002338647,0.0001532978,0.00008160218,0.00005410854,0.0002590163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9875348,0.002049742,0.0001574285,0.0006084404,0.0007333255,0.00003164135,0.00002611346,0.0001408696,0.002034953,0.00004964925,0.0004370505,0.006195964],"study_design_scores_gemma":[0.9684559,0.03003582,0.0005630013,0.00001963882,0.0002653125,0.00002308754,0.00001261393,0.0001114613,0.0001623889,0.00005257073,0.0002884323,0.000009744214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9774423,0.0106145,0.001161238,0.001034736,0.00155044,0.00405509,0.001657396,0.0002075732,0.002276786],"genre_scores_gemma":[0.9750404,0.008121771,0.001882764,0.001629477,0.001014116,0.004622966,0.00174903,0.00006577944,0.005873606],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008329206,"threshold_uncertainty_score":0.02786398,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0695716841107646,"score_gpt":0.374972235833241,"score_spread":0.3054005517224764,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}